Cetuximab for the Treatment of Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. METHODS: From December 2003 to August 2005, 572 patients who had colorectal cancer expressing immunohistochemically detectable EGFR and who had been previously treated with a fluoropyrimidine, irinotecan, and oxaliplatin or had contraindications to treatment with these drugs underwent randomization to an initial dose of 400 mg of cetuximab per square meter of body-surface area followed by a weekly infusion of 250 mg per square meter plus best supportive care (287 patients) or best supportive care alone (285 patients). The primary end point was overall survival. RESULTS: In comparison with best supportive care alone, cetuximab treatment was associated with a significant improvement in overall survival (hazard ratio for death, 0.77; 95% confidence interval [CI], 0.64 to 0.92; P=0.005) and in progression-free survival (hazard ratio for disease progression or death, 0.68; 95% CI, 0.57 to 0.80; P<0.001). These benefits were robust after adjustment in a multivariable Cox proportional-hazards model. The median overall survival was 6.1 months in the cetuximab group and 4.6 months in the group assigned to supportive care alone. Partial responses occurred in 23 patients (8.0%) in the cetuximab group but in none in the group assigned to supportive care alone (P<0.001); the disease was stable in an additional 31.4% of patients assigned to cetuximab and in 10.9% of patients assigned to supportive care alone (P<0.001). Quality of life was better preserved in the cetuximab group, with less deterioration in physical function and global health status scores (both P<0.05). Cetuximab treatment was associated with a characteristic rash; a rash of grade 2 or higher was strongly associated with improved survival (hazard ratio for death, 0.33; 95% CI, 0.22 to 0.50; P<0.001). The incidence of any adverse event of grade 3 or higher was 78.5% in the cetuximab group and 59.1% in the group assigned to supportive care alone (P<0.001). CONCLUSIONS: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed. (ClinicalTrials.gov number, NCT00079066 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cetuximab is a chimeric (mouse/human) monoclonal IgG1 antibody developed to bind the extracellular EGFR domain that blocks dimerization and ligand-induced signaling of the EGFR pathway [14].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
In the citing paper
“Patients who received cetuximab had a 6.1-month median survival compared with 4.6 months among individuals in the best supportive care group.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [14]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Self-citationGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The EGF receptor family as targets for cancer therapy
Mendelsohn, J., & Baselga, J. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,340
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Research works printed but not linked: 3
- Mellstedt H, 2003, Drugs Today (Barc), 39, 1
- Eng C, 2007, J Clin Oncol, 25, 18s
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
Cited by
Items 601–700 of 1,001
Porret, E., Kereselidze, D., Dauba, A., Schweitzer-Chaput, A., Jegot, B., Selingue, E., Tournier, N., Larrat, B., Novell, A., & Truillet, C. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.12.006 · Cited by 34
Balko, J. M., & Black, E. P. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-145 · Cited by 38
Shigeta, K., Hayashida, T., Hoshino, Y., Okabayashi, K., Endo, T., Ishii, Y., Hasegawa, H., & Kitagawa, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066302 · Cited by 39
Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer
Hocking, C. M., & Price, T. J. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13498660 · Cited by 36
Self-citationAntibody-Based Therapy in Colorectal Cancer
Noguchi, T., Ritter, G., & Nishikawa, H. (2013) · Immunotherapy · doi:10.2217/imt.13.35 · Cited by 34
Personalizing Therapy for Colorectal Cancer
Wong, C. Y., & Ma, B. B. Y. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.08.040 · Cited by 37
Lee, M. S., & Kopetz, S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.05.006 · Cited by 41
Eng, C., Lakhani, N. J., Philip, P. A., Schneider, C. J., Johnson, B., Kardosh, A., Chao, M. P., Patnaik, A., Shihadeh, F. D., Lee, Y., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01130-y · Cited by 46
Páez, D., Paré, L., Espinosa, Í., Salazar, J., del Río, E., Barnadas, A., Marcuello, E., & Baiget, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01621.x · Cited by 37
Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer
Kalva, S. P., Rana, R. S., Liu, R., Rachamreddy, N., Dave, B. R., Sharma, A. M., Ganguli, S., Rabito, C. A., Kwak, E. L., & Blaszkowsky, L. S. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000151 · Cited by 32
Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines.
Wu, W. K. K., Tse, T. T. M., Sung, J. J. �., Li, Z. J., Yu, L., & Cho, C. H. (2009) · PubMed · Cited by 32
Biological agents in gastrointestinal cancers: adverse effects and their management
Arora, N., Gupta, A., & Singh, P. P. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.07 · Cited by 37
Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector–Host Interactions
Weklak, D., Pembaur, D., Koukou, G., Jönsson, F., Hagedorn, C., & Kreppel, F. (2021) · Viruses · doi:10.3390/v13071300 · Cited by 36
Emerging trends in the application of gold nanoformulations in colon cancer diagnosis and treatment
Aldahhan, R., Almohazey, D., & Khan, F. A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.008 · Cited by 39
The role of targeted agents in preoperative chemoradiation for rectal cancer
Wadlow, R. C., & Ryan, D. P. (2010) · Cancer · doi:10.1002/cncr.25155 · Cited by 35
Wierzbicki, R. F., Jonker, D. J., Moore, M. J., Berry, S. R., Loehrer, P. J., Youssoufian, H., & Rowinsky, E. K. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9341-6 · Cited by 34
“Lastly, 23 (8%) patients with refractory mCRC whose tumors demonstrated EGFR immunostaining achieved a PR in a phase III cetuximab monotherapy study by Jonker et al [ 9 ].”
BackgroundSelf-citationPatel, D. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.11-supp.31s · Cited by 35
Lévi, F., Karaboué, A., Étienne-Grimaldi, M.-C., Paintaud, G., Focan, C., Innominato, P. F., Bouchahda, M., Milano, G. A., & Chatelut, É. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0431-2 · Cited by 32
“The relevance of this companion study is further supported by a 30 % LM-CRC conversion-to-resection rate, despite protocol application as the median third-line chemotherapy, and a median overall survival (OS) of 25 months in this poor-prognosis patient population [9].”
BackgroundInfluentialNakajima, J., Iida, T., Okumura, S., Horio, H., Asamura, H., Ozeki, Y., Ikeda, N., Matsuguma, H., Chida, M., Otsuka, H., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw401 · Cited by 32
“targeted drugs bevacizumab [5, 14], cetuximab [15] and panitumumab [16].”
BackgroundCamelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling
Rossotti, M. A., Henry, K. A., van Faassen, H., Tanha, J., Callaghan, D., Hussack, G., Arbabi‐Ghahroudi, M., & MacKenzie, C. R. (2018) · Biochemical Journal · doi:10.1042/bcj20180795 · Cited by 32
Mallmann-Gottschalk, N., Sax, Y., Kimmig, R., Lang, S., & Brandau, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194693 · Cited by 31
“approved for the treatment of metastatic colorectal cancer and advanced head and neck cancer [7,8].”
BackgroundNukatsuka, M., Nakagawa, F., & Takechi, T. (2015) · PubMed · Cited by 31
Advances and new perspectives in the treatment of metastatic colon cancer
Recondo, G. (2014) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v6.i7.211 · Cited by 34
Critical comments for roles of biomarkers in the diagnosis and treatment of cancer
Saijo, N. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.02.004 · Cited by 35
Harbison, C. T., Horak, C. E., Ledeine, J.-M., Mukhopadhyay, P., Malone, D. P., O’Callaghan, C. J., Jonker, D. J., Karapetis, C. S., Khambata‐Ford, S., Gustafson, N., et al. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0367-oa · Cited by 34
Self-citationOcaña, A., Ethier, J.-L., Díez-González, L., Corrales‐Sánchez, V., Srikanthan, A., Gascón-Escribano, M. J., Templeton, A. J., Vera-Badillo, F., Šeruga, B., Niraula, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5946 · Cited by 32
Hu, S., Dai, H., Li, T. X., Tang, Y., Fu, W., Yuan, Q., Wang, F., Lv, G., Lv, Y., Fan, X., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.022 · Cited by 31
Hu, Y., Ma, Z., He, Y., Liu, W., Su, Y., & Tang, Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.042 · Cited by 31
The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine
Riley, J. M., Cross, A. W., Paulos, C. M., Rubinstein, M. P., Wrangle, J. M., & Camp, E. R. (2018) · Cancer · doi:10.1002/cncr.31214 · Cited by 37
Jhawat, V., Gulia, M., Gupta, S., Maddiboyina, B., & Dutt, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.039 · Cited by 36
Directly reprogrammed natural killer cells for cancer immunotherapy
Kim, H., Kim, J. Y., Seol, B., Song, C. L., Jeong, J. E., & Cho, Y. S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00768-z · Cited by 31
Yoshida, M., Shimura, T., Sato, M., Ebi, M., Nakazawa, T., Takeyama, H., & Joh, T. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1340-x · Cited by 32
Predictive value of KRAS mutations in chemoresistant CRC
Lièvre, A., & Laurent‐Puig, P. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.69 · Cited by 38
Systemic chemotherapy and its implications for resection of colorectal liver metastasis
Robinson, S. M., Manas, D., Pedley, I. D., Mann, D. A., & White, S. A. (2009) · Surgical Oncology · doi:10.1016/j.suronc.2009.10.002 · Cited by 32
Guo, Y., Parry, J. J., Laforest, R. A., Rogers, B. E., & Anderson, C. J. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.118539 · Cited by 31
Ochoa, M. C., Minute, L., López, A., Pérez-Ruiz, E., Gomar, C., Vásquez, M., Inogés, S., Etxeberría, I., Rodríguez, I., Garasa, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1393597 · Cited by 31
Tsigelny, I. F., Wheler, J. J., Greenberg, J. P., Kouznetsova, V. L., Stewart, D. J., Bazhenova, L., & Kurzrock, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3472 · Cited by 30
“Antitumor activity of cetuximab is observed in patients with EGFR wild-type colorectal and head and neck cancers, but not in many other tumor types [10–12].”
BackgroundCell signaling pathways based on vitamin C and their application in cancer therapy
Fan, D., Liu, X., Shen, Z., Wu, P., Zhong, L., & Lin, F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114695 · Cited by 33
Li, Y., Wang, B., Yang, W., Ma, F., Zou, J., Li, K., Tan, S., Feng, J., Wang, Y., Qin, Z., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44911-1 · Cited by 38
Fornaro, L., Baldi, G. G., Masi, G., Allegrini, G., Loupakis, F., Vasile, E., Cupini, S., Stasi, I., Salvatore, L., Cremolini, C., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.06.003 · Cited by 31
Lee, R. T., Ramchandran, K. J., Sanft, T. B., & Roenn, J. V. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv207 · Cited by 33
Employing dynamical computational models for personalizing cancer immunotherapy
Agur, Z., Halevi-Tobias, K., Kogan, Y., & Shlagman, O. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1223622 · Cited by 33
Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment
Verdaguer, H., Saurí, T., & Macarulla, T. M. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.15 · Cited by 36
Subbiah, V., Khawaja, M. R., Hong, D. S., Amini, B., Yungfang, J., Liu, H., Johnson, A., Schrock, A. B., Ali, S. M., Sun, J. X., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90380 · Cited by 30
Funakoshi, T., Suzuki, M., & Tamura, K. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.09.002 · Cited by 31
“Jonker, 2007 [28] III Openlabel Colorectal cancer Cetuximab + BSC 572 288 63 (29–88) 2.”
BackgroundRay, G. L., Baidoo, K. E., Wong, K. J., Williams, M. R. C., Garmestani, K., Brechbiel, M. W., & Milenic, D. E. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00327.x · Cited by 30
Sohn, B. S., Park, S., Kim, J. E., Kim, K., Hong, Y. S., Suh, C., Kim, Y. S., Kim, S., Im, S., Kim, S., et al. (2014) · Oncology · doi:10.1159/000365593 · Cited by 33
Shimoyama, S. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1583-2 · Cited by 33
“In addition, cetuximab produced longer overall survival than did the best supportive care alone [ 28 ].”
BackgroundDesign of clinical trials for biomarker research in oncology
Mandrekar, S. J., & Sargent, D. J. (2011) · Clinical Investigation · doi:10.4155/cli.11.152 · Cited by 36
Biomarkers in colorectal cancer
Markman, B., Rodríguez-Freixinós, V., & Tabernero, J. M. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0502-z · Cited by 35
“An unplanned retrospective analysis from the CO.17 study revealed that the development of a moderate or worse skin rash with cetuximab treatment was strongly associated with OS [ 63 ].”
MethodBaynes, R. D., & Gansert, J. L. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e318199fa17 · Cited by 33
Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab
Rodríguez, J., Viúdez, A., Ponz‐Sarvisé, M., Gil-Aldea, I., Chopitea, A., García‐Foncillas, J., & Bazo, I. G. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.07.005 · Cited by 32
Hansen, N. L., Chandiramani, D. V., Morse, M. A., Wei, D., Hedrick, N. E., & Hansen, R. A. (2010) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155209360853 · Cited by 31
Davies, J. M., Trembath, D. G., Deal, A. M., Funkhouser, W. K., Calvo, B. F., Finnegan, T., Weck, K. E., Tepper, J. E., & O’Neil, B. H. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-114 · Cited by 30
Pozzo, C., & Barone, C. A. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0082 · Cited by 30
Maithel, S. K., Gönen, M., Ito, H., DeMatteo, R. P., Allen, P. J., Fong, Y., Blumgart, L. H., Jarnagin, W. R., & D'Angelica, M. I. (2011) · Surgery · doi:10.1016/j.surg.2011.07.020 · Cited by 30
Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis
Kogita, A., Yoshioka, Y., Sakai, K., Togashi, Y., Sogabe, S., Nakai, T., Okuno, K., & Nishio, K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.064 · Cited by 29
EGFR signaling in colorectal cancer: a clinical perspective
Frattini, M., Saletti, P., Molinari, F., & Dosso, S. D. (2015) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s49002 · Cited by 45
Blaszkowsky, L. S., Ryan, D. P., Szymonifka, J. D., Borger, D. R., Zhu, A. X., Clark, J. W., Kwak, E. L., Mamon, H. J., Allen, J. N., Vasudev, E., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt516 · Cited by 29
Bekaii‐Saab, T., & Wu, C. S.-Y. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.01.001 · Cited by 30
“17 trial supported this rationale by emonstrating a benefit with cetuximab monotherapy comared with best supportive care [26].”
BackgroundGarrett, C. R., Siu, L. L., El-Khoueiry, A. B., Buter, J., Rocha‐Lima, C., Marshall, J. L., LoRusso, P. M., Major, P. P., Chemidlin, J., Mokliatchouk, O., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.182 · Cited by 32
Tanishima, H., Tominaga, T., Kimura, M., Maeda, T., Shirai, Y., & Horiuchi, T. (2016) · Supportive Care in Cancer · doi:10.1007/s00520-016-3514-6 · Cited by 29
“The skin rash induced by cetuximab has been shown to be a potential predictive marker, although this finding has not been validated [27, 28].”
BackgroundCutaneous Squamous Cell Carcinoma in the Age of Immunotherapy
Ishitsuka, Y., Hanaoka, Y., Tanemura, A., & Fujimoto, M. (2021) · Cancers · doi:10.3390/cancers13051148 · Cited by 29
Ikoma, T., Shimokawa, M., Kotaka, M., Matsumoto, T., Nagai, H., Boku, S., Shibata, N., Yasui, H., & Satake, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08271-z · Cited by 33
Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
Si, Y., Zhang, Y., Ngo, H. G., Guan, J.-S., Chen, K., Wang, Q., Singh, A. P., Xu, Y., Zhou, L., Yang, E. S.-H., et al. (2021) · Cancers · doi:10.3390/cancers13153749 · Cited by 30
McFall, T. B., & Stites, E. C. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110096 · Cited by 31
“RAS mutations were among the first actionable biomarkers, in which the presence of a KRAS mutation in a colorectal cancer (CRC) indicated resistance to treatments that target the epidermal growth factor receptor (EGFR) (Jonker et al., 2007).”
Donahue, T. C., Ou, C., Yang, Q., Flinko, R., Zhang, X., Zong, G., Lewis, G. K., & Wang, L. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00229 · Cited by 33
Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC)
Stintzing, S., Stremitzer, S., Sebio, A., & Lenz, H. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.09.009 · Cited by 33
Montagut, C. O., Iglesias, M., Arumí, M., Bellosillo, B., Gallén, M., Martinez-Fernandez, A., Martinez-Aviles, L. M., Cañadas, I., Dalmases, A., Moragón, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605612 · Cited by 31
EGFR-targeting agents in oncology
Garofalo, S., Rosa, R., Bianco, R., & Tortora, G. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.8.889 · Cited by 30
Why RECIST Works and Why It Should Stay—Counterpoint
Fojo, A. T., & Noonan, A. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0733 · Cited by 30
Stintzing, S., von Weikersthal, L. F., Vehling‐Kaiser, U., Stauch, M. B., Hass, H. G., Dietzfelbinger, H., Oruzio, D. V., Klein, S., Zellmann, K., Decker, T. W., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.227 · Cited by 33
Ghatalia, P., Morgan, C. J., & Sonpavde, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.018 · Cited by 31
An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma
Ikoma, N., Raghav, K. P. S., & Chang, G. J. (2017) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.05.007 · Cited by 38
Henry, J. T., & Johnson, B. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.08.08 · Cited by 29
Xie, H., Lafky, J. M., Morlan, B. W., Stella, P. J., Dakhil, S. R., Gross, G. G., Loui, W. S., Hubbard, J. M., Alberts, S. R., & Grothey, A. F. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920910913 · Cited by 29
Colorectal Cancer: Therapeutic Approaches and Their Complications
Adebayo, A. S., Adeleke, A., Adesina, S. K., Agbaje, K. O., & Olajubutu, O. (2025) · Biomedicines · doi:10.3390/biomedicines13071646 · Cited by 32
“%) who had earlier been treated with fluorouracil combined with either oxaliplatin or irinotecan, after being treated with panitumumab [56].”
The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer
Hendlisz, A., Deleporte, A., Delaunoit, T., Maréchal, R., Peeters, M., Holbrechts, S., den Eynde, M. V., Houbiers, G., Filleul, B., Laethem, J. V., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138341 · Cited by 28
Balagula, Y., Wu, S., Su, X., & Lacouture, M. E. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr016 · Cited by 28
“Cetuximab monotherapy is Food and Drug Administration- approved for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) and EGFR-expressing metastatic colorectal carcinoma (mCRC) [10, 11].”
BackgroundPower, D. G., Shah, M. A., Asmis, T. R., García, J. J., & Kemeny, N. E. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9268-y · Cited by 28
“Cmab has demonstrated activity alone and in combination with chemotherapy for the first, second and third-line settings in the treatment of mCRC [1–10].”
BackgroundResultAssoun, S., Lemiale, V., & Azoulay, É. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05650-w · Cited by 32
Montés, A. F., Grávalos, C., Pericay, C., Safont, M. J., Benavides, M., Élez, E., Alfonso, P. G., García-Paredes, B., Carrato, A., & Aranda, E. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.04.003 · Cited by 29
Vasseur, D., Sassi, H., Bayle, A., Tagliamento, M., Besse, B., Marzac, C., Arbab, A., Auger, N., Cotteret, S., Aldea, M. D., et al. (2022) · Cells · doi:10.3390/cells11121901 · Cited by 28
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Liu, L., & Chen, J. (2022) · Medical Review · doi:10.1515/mr-2022-0033 · Cited by 29
Dougan, M. L., & Dranoff, G. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9914-6_22 · Cited by 35
Pietrantonio, F., Perrone, F., Biondani, P., Maggi, C., Lampis, A., Bertan, C., Venturini, F., Tondulli, L., Ferrari, D., Ricci, V., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26343 · Cited by 28
Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer
Khattak, M. A., Townsend, A. R., Beeke, C., Karapetis, C. S., Luke, C., Padbury, R., Maddern, G. J., Roder, D. M., & Price, T. J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.029 · Cited by 31
Self-citationSun, X., Peng, P., & Tu, D. (2010) · Contemporary Clinical Trials · doi:10.1016/j.cct.2010.09.009 · Cited by 28
“In a recent phase III trial of cetuximabversus best supportive care in the treatment of metastatic colorectal cancer [6], Kaplan–Meier curves for the progression-free survival started to separate after the median, which implies the median survival time may also not be a sensitive endpoint”
BackgroundSelf-citationExtended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers.
Al-Shamsi, H. O., Alhazzani, W. A., & Wolff, R. A. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2015.016 · Cited by 34
Yamaguchi, K., Watanabe, T., Satoh, T., Ishiguro, M., Izawa, M., Inoshiri, S., Sugihara, K., & Sakata, Y. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu049 · Cited by 28
Aglietta, M., Barkholt, L., Schianca, F. C., Caravelli, D., Omazic, B., Minotto, C., Leone, F., Hentschke, P., Bertoldero, G., Capaldi, A., et al. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2008.11.036 · Cited by 32
Chirurgie des métastases pulmonaires des cancers colorectaux : facteurs prédictifs de survie
Pagès, P., Pimpec‐Barthes, F. L., & Bernard, A. (2016) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2016.02.006 · Cited by 28
“[61] Jonker DJ, O’Callaghan CJ, Karapetis CS, et al.”
The pharmacogenomics of drug resistance to protein kinase inhibitors
Gillis, N., & McLeod, H. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.008 · Cited by 33
Kienle, D., Dietrich, D., Ribi, K., WICKI, A. N., Quagliata, L., Winterhalder, R. C., Koeberle, D., Horber, D., Bastian, S., Kueng, M., et al. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.11.011 · Cited by 30
The Economic Impact of the Transition from Branded to Generic Oncology Drugs
Cheung, W. Y., Kornelsen, E., Mittmann, N., Leighl, N. B., Cheung, M. C., Chan, K., Bradbury, P. A., Ng, R. C. H., Chen, B. E., Ding, K., et al. (2019) · Current Oncology · doi:10.3747/co.26.4395 · Cited by 28
Self-citationShepherd, F. A., & Tsao, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3996 · Cited by 34
Augustine, T. A., Baig, M., Sood, A., Budagov, T., Atzmon, G., Mariadason, J. M., Aparo, S., Maitra, R., & Goel, S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.561 · Cited by 27
“…metastatic CRC (mCRC) has improved to 24–30 months (Goldberg et al, 2007) mainly because of the availability of newer therapeutic option of epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies (mAb) such as cetuximab and panitumumab (Tournigand et al, 2004; Jonker et al, 2007).”
BackgroundCetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence?
Norguet, E., Dahan, L., Gaudart, J., Gasmi, M., Ouafik, L., & Seitz, J. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2011.06.002 · Cited by 29
“initiation (months) Number of courses of CTX 7 [1–16] 6 [2–21] 0.”
BackgroundInfluentialHigaki, E., Kuwata, T., Nagatsuma, A. K., Nishida, Y., Kinoshita, T., Aizawa, M., Nitta, H., Nagino, M., & Ochiai, A. (2014) · Gastric Cancer · doi:10.1007/s10120-014-0449-9 · Cited by 29
Targeted Therapeutic Agents for Colorectal Cancer
Chee, C. E., & Sinicrope, F. A. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.08.017 · Cited by 29
Metadata
- Authors
- Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., Tebbutt, N. C., van Hazel, G., Wierzbicki, R., Langer, C., & Moore, M. J.
- Affiliations
- University of Ottawa (CA)
- Flinders Medical Centre (AU)
- The University of Melbourne (AU)
- Queen's University (CA)
- Cross Cancer Institute (CA)
- Sunnybrook Health Science Centre (CA)
- St. Boniface Hospital (CA)
- Queen Elizabeth Hospital (AU)
- The University of Sydney (AU)
- Austin Health (AU)
- Lakeridge Health (CA)
- Bristol-Myers Squibb (United States) (US)
- Princess Margaret Cancer Centre (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2040-2048
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115790682
- Cited by
- 1,904
- References
- 20
- Citations by year
- 2026: 23 · 2025: 47 · 2024: 56 · 2023: 60 · 2022: 62 · 2021: 63 · 2020: 87 · 2019: 82 · 2018: 84 · 2017: 101 · 2016: 110 · 2015: 133 · 2014: 143 · 2013: 150 · 2012: 153
- FWCI
- 68.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- cetuximab, colorectal cancer, epidermal growth factor receptor, EGFR-positive tumors, monoclonal antibody therapy, best supportive care, overall survival, progression-free survival, rash, quality of life, adverse events, irinotecan, oxaliplatin, fluoropyrimidine
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Exanthema, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Colorectal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.